➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
McKesson
Johnson and Johnson
Dow

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LIK066


Email this page to a colleague

« Back to Dashboard

What is the drug development status for LIK066?

LIK066 is an investigational drug.

There have been 12 clinical trials for LIK066. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Overweight. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are six US patents protecting this investigational drug and eighty international patents.

Recent Clinical Trials for LIK066
TitleSponsorPhase
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin Compared to Each Monotherapy, in Adult Patients With NASH and Liver Fibrosis.Novartis PharmaceuticalsPhase 2
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With ObesityNovartis PharmaceuticalsPhase 2
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese PatientsNovartis PharmaceuticalsPhase 2

See all LIK066 clinical trials

Clinical Trial Summary for LIK066

Top disease conditions for LIK066
Top clinical trial sponsors for LIK066

See all LIK066 clinical trials

US Patents for LIK066

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LIK066   Try Before You Buy C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof YOUNGENE THERAPEUTICS CO., LTD (China (Shanghai) Pilot Free Trade Zone, CN)   Try Before You Buy
LIK066   Try Before You Buy Glycoside derivatives and uses thereof Novartis AG (Basel, CH)   Try Before You Buy
LIK066   Try Before You Buy Glycoside derivatives and uses thereof Novartis AG (Basel, CH)   Try Before You Buy
LIK066   Try Before You Buy Glycoside derivatives and uses thereof Novartis AG (Basel, CH)   Try Before You Buy
LIK066   Try Before You Buy Glycoside derivatives and uses thereof Novartis AG (Basel, CH)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LIK066

Drugname Country Document Number Estimated Expiration Related US Patent
LIK066 Australia AU2014317663 2033-09-09   Try Before You Buy
LIK066 Canada CA2923522 2033-09-09   Try Before You Buy
LIK066 China CN105518014 2033-09-09   Try Before You Buy
LIK066 China CN107311992 2033-09-09   Try Before You Buy
LIK066 European Patent Office EP3056507 2033-09-09   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Medtronic
AstraZeneca
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.